Bildkälla: Stockfoto

BioInvent Q3 2024: New Positive BI-1206 SC Data - Redeye

Redeye comments on BioInvent's Q3 report, which presented new data for the subcutaneous version of BI-1206 in combination with rituximab in lymphoma.

Redeye comments on BioInvent's Q3 report, which presented new data for the subcutaneous version of BI-1206 in combination with rituximab in lymphoma.
Börsvärldens nyhetsbrev
ANNONSER